Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO9L38)

• Drug Name: [3H]SB-674042 Drug Info
• Synonyms: CHEMBL2413521; [3H]SB-674042; GTPL1706

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 73349109
  TTD Drug ID: DMO9L38

Molecule-Related Drug Atlas

Drug(s) Targeting Orexin receptor type 2 (HCRTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Suvorexant	DM0E6S3	Insomnia	7A00-7A0Z	Approved	[4]
MK-3697	DM347TQ	Insomnia	7A00-7A0Z	Phase 2	[5]
MIN-202	DMZFW8V	Major depressive disorder	6A70.3	Phase 2	[6]
TAK-861	DMLGEQ7	Narcolepsy type 1	7A20.0	Phase 2	[7]
TAK-925	DM7N4H9	Narcolepsy	7A20	Phase 1	[8]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[9]

Drug(s) Targeting Orexin receptor type 1 (HCRTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SB-649868	DMYLBOU	Insomnia	7A00-7A0Z	Phase 2	[10]
JNJ-61393215	DME2S4D	Major depressive disorder	6A70.3	Phase 2	[11]
AZD4041	DMEPQI4	Opioid use disorder	6C43.2Z	Phase 1	[12]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 9	DM7I8ZV	N. A.	N. A.	Patented	[9]
1,2-diamino cyclopentane-based derivative 8	DM7JX8U	N. A.	N. A.	Patented	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Orexin receptor type 1 (HCRTR1)	TT60Q8D	OX1R_HUMAN	Antagonist	[2]
Orexin receptor type 2 (HCRTR2)	TT9N02I	OX2R_HUMAN	Antagonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1706).
• [2] Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol. 2010 Jul;78(1):81-93.
• [3] Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [8] Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902.
• [9] Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
• [10] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [11] Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308.
• [12] Clinical pipeline report, company report or official report of AstraZeneca